6-Bnz-cAMP sodium salt
(Synonyms: 6-Bnz-cAMP) 目录号 : GC12834A PKA-selective activator
Cas No.:1135306-29-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
6-Bnz-cAMP is a PKA-selective activator. It regulates the PKA dependent signaling pathways.
Like PKA contains an evolutionally conserved cAMP-binding domain that acts as a molecular switch for sensing intracellular second messenger cAMP levels to control diverse biological functions. CAMP response element-binding protein (CREB) is the well-known direct target protein of PKA. Phosphorylation of CREB (pCREB) by PKA has been shown to be involved in regulating osteoblast differentiation.
The proliferative signaling pathway which activated by the 6-Bnz-cAMP involves activation of the epidermal growth factor receptor and ERK1/2. Extending the duration of PKA-dependent ERK1/2 activation and converted cAMP from a proliferative into an anti-proliferative, neurite outgrowth- promoting signal.
6-Bnz-cAMP can promote not only differentiation and mineralization, but also initial cell adhesion.6-Bnz-cAMP is able to induce osteogenic differentiation of MC3T3-E1 cells. Moreover 6-Bnz-cAMP may facilitate release kinetic from a tissue-engineered polymeric scaffold system. It also can serve as a novel bone-inducing growth factor for repairing and regenerating bone tissues during bone regenerative engineering.
References:
[1]Lo KW, Kan HM, Ashe KM, Laurencin CT. The small molecule PKA-specific cyclic AMP analogue as an inducer of osteoblast-like cells differentiation and mineralization. J Tissue Eng Regen Med. 2012 Jan;6(1):40-8.
[2]Simone Kiermayer, Ricardo M. Biondi,etal., Epac Activation Converts cAMP from a Proliferative into a Differentiation Signal in PC12 Cells. Molecular Biology of the Cell. Vol. 16, 5639–5648, December 2005.
[3]Cheng X, Ji Z, Tsalkova T, Mei F. Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin (Shanghai). 2008 Jul;40(7):651-62.
Cas No. | 1135306-29-4 | SDF | |
别名 | 6-Bnz-cAMP | ||
化学名 | sodium (4aR,6R,7R,7aS)-6-(6-benzamido-9H-purin-9-yl)-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide | ||
Canonical SMILES | O=C(NC1=NC=NC2=C1N=CN2[C@@H]3O[C@@](COP(O4)(O[Na])=O)([H])[C@]4([H])[C@H]3O)C5=CC=CC=C5 | ||
分子式 | C17H15N5NaO7P | 分子量 | 455.29 |
溶解度 | PBS (pH 7.2): 3 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1964 mL | 10.982 mL | 21.964 mL |
5 mM | 0.4393 mL | 2.1964 mL | 4.3928 mL |
10 mM | 0.2196 mL | 1.0982 mL | 2.1964 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。